<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We compared the antithrombotic efficacy of FK419 [(S)-2-acetylamino-3-[(R)-[1-[3-(piperidin-4-yl)<z:chebi fb="0" ids="26294">propionyl</z:chebi>]piperidin-3-ylcarbonyl]amino] <z:chebi fb="0" ids="30768">propionic acid</z:chebi> trihydrate], a novel nonpeptide <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi>, with recombinant tissue plasminogen activator (rt-PA) and other antithrombotic agents (aspirin, ozagrel, argatroban and <z:chebi fb="5" ids="28304">heparin</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>FK419 not only inhibited <z:chebi fb="13" ids="16761">ADP</z:chebi>- and collagen-induced guinea pig platelet aggregation, but also induced disaggregation for <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced aggregated platelets in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>In the photochemically induced middle cerebral artery <z:mp ids='MP_0005048'>thrombosis</z:mp> model in guinea pigs, FK419 dose-dependently shortened the time to first reperfusion and the total middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> time and reduced ischemic brain damage and ameliorated neurological deficits measured 24 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Rt-PA similarly improved the middle cerebral artery patency, brain damage and neurological deficits </plain></SENT>
<SENT sid="4" pm="."><plain>Neither aspirin, ozagrel, argatroban nor <z:chebi fb="5" ids="28304">heparin</z:chebi> restored the middle cerebral artery blood flow and improved the brain damage or neurological deficits </plain></SENT>
<SENT sid="5" pm="."><plain>These results demonstrated that novel <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> FK419 could disperse <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and ameliorated ischemic brain damage, suggesting that FK419 would be an attractive intervention for <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>